Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma

Stefano Ferrari, Emanuela Palmerini

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In recent years, clinical research has essentially focused on possible refinements of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) therapy rather than investigating new drugs. It has been demonstrated that dose-intensification does not improve prognosis. Many investigators have evaluated late chemotherapy-related side effects, particularly in terms of cardiac, renal and auditive toxicity, risk of infertility and of second tumors. Recent findings recommend further studies to define the role of the immunostimulating agent muramyl tripeptide- phosphatidilethanolamine in osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves further clinical studies. SUMMARY: At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by dose intensification of treatment and new strategies are required. Prolonged follow-up is mandatory due to the risk of late effects, second tumors and late relapse from osteosarcoma.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalCurrent Opinion in Oncology
Volume19
Issue number4
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Osteosarcoma
Combination Drug Therapy
Drug Therapy
Ifosfamide
Methotrexate
Doxorubicin
Cisplatin
Sirolimus
Pharmaceutical Preparations
Infertility
Neoplasms
Therapeutics
Survival Rate
Extremities
Research Personnel
Clinical Trials
Kidney
Recurrence
Research

Keywords

  • Chemotherapy
  • Neoadjuvant chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. / Ferrari, Stefano; Palmerini, Emanuela.

In: Current Opinion in Oncology, Vol. 19, No. 4, 07.2007, p. 341-346.

Research output: Contribution to journalArticle

@article{a7cd9c9991e84885bce3f14aaa10278f,
title = "Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma",
abstract = "PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In recent years, clinical research has essentially focused on possible refinements of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) therapy rather than investigating new drugs. It has been demonstrated that dose-intensification does not improve prognosis. Many investigators have evaluated late chemotherapy-related side effects, particularly in terms of cardiac, renal and auditive toxicity, risk of infertility and of second tumors. Recent findings recommend further studies to define the role of the immunostimulating agent muramyl tripeptide- phosphatidilethanolamine in osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves further clinical studies. SUMMARY: At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70{\%} with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by dose intensification of treatment and new strategies are required. Prolonged follow-up is mandatory due to the risk of late effects, second tumors and late relapse from osteosarcoma.",
keywords = "Chemotherapy, Neoadjuvant chemotherapy, Osteosarcoma",
author = "Stefano Ferrari and Emanuela Palmerini",
year = "2007",
month = "7",
doi = "10.1097/CCO.0b013e328122d73f",
language = "English",
volume = "19",
pages = "341--346",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma

AU - Ferrari, Stefano

AU - Palmerini, Emanuela

PY - 2007/7

Y1 - 2007/7

N2 - PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In recent years, clinical research has essentially focused on possible refinements of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) therapy rather than investigating new drugs. It has been demonstrated that dose-intensification does not improve prognosis. Many investigators have evaluated late chemotherapy-related side effects, particularly in terms of cardiac, renal and auditive toxicity, risk of infertility and of second tumors. Recent findings recommend further studies to define the role of the immunostimulating agent muramyl tripeptide- phosphatidilethanolamine in osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves further clinical studies. SUMMARY: At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by dose intensification of treatment and new strategies are required. Prolonged follow-up is mandatory due to the risk of late effects, second tumors and late relapse from osteosarcoma.

AB - PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In recent years, clinical research has essentially focused on possible refinements of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) therapy rather than investigating new drugs. It has been demonstrated that dose-intensification does not improve prognosis. Many investigators have evaluated late chemotherapy-related side effects, particularly in terms of cardiac, renal and auditive toxicity, risk of infertility and of second tumors. Recent findings recommend further studies to define the role of the immunostimulating agent muramyl tripeptide- phosphatidilethanolamine in osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves further clinical studies. SUMMARY: At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by dose intensification of treatment and new strategies are required. Prolonged follow-up is mandatory due to the risk of late effects, second tumors and late relapse from osteosarcoma.

KW - Chemotherapy

KW - Neoadjuvant chemotherapy

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=34249999670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249999670&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328122d73f

DO - 10.1097/CCO.0b013e328122d73f

M3 - Article

C2 - 17545797

AN - SCOPUS:34249999670

VL - 19

SP - 341

EP - 346

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -